TB-500 and the heart: the cardiac papers are about thymosin beta-4, not the fragment

There is a real cardiac literature here, and it is more interesting than most research-peptide threads. There is also a substitution that happens almost every time it is summarised, and it changes what the literature means.

The papers are about thymosin beta-4. TB-500 is not thymosin beta-4. Getting that distinction right is the whole point of this article, so it comes first.

Two different molecules with one name between them

Thymosin beta-4 is a 43-residue actin-sequestering protein, present in most cell types, with a job in cytoskeletal regulation: it binds monomeric G-actin and controls how readily it polymerises. Cells that need to change shape and move depend on that control.

TB-500 is a name attached to a synthetic fragment — in most supply it is the short actin-binding motif from the middle of the parent sequence, LKKTETQ, usually acetylated. Seven residues against forty-three. The motif is the part that carries the actin-binding function, which is the reason it was chosen.

The naming is genuinely confused across the industry. Some suppliers sell full-length thymosin beta-4 under the TB-500 label; catalogue entries routinely pair the seven-residue sequence with the full protein's molecular weight, which cannot both describe the same vial. Anyone reading a specification should check the mass against the sequence, because the two molecules are not interchangeable and the papers below used one of them.

What the cardiac papers examined

Bock-Marquette and colleagues, Nature, 2004 (PMID 15565145). The anchor reference. The paper reported that thymosin beta-4 promoted migration of cardiomyocytes and cardiac progenitor cells, improved cardiac cell survival, and activated integrin-linked kinase, which gave the finding a named intracellular pathway rather than a bare observation. In a mouse coronary-ligation model of myocardial infarction, treated animals were reported to show better recovery of cardiac function and less scarring.

It landed in Nature for a specific reason. Adult mammalian cardiomyocytes barely divide. The heart does not replace lost muscle the way skin or gut lining replaces lost cells — it scars. A reported functional improvement in that tissue is unusual enough to be worth a high-profile paper.

Smart and colleagues, Nature, 2007. Examined thymosin beta-4 and reported mobilisation of adult epicardial progenitor cells and new vessel formation. The epicardium — the outer layer of the heart — holds progenitor populations, and whether they can be recruited after injury is one of the live questions in the field.

Reviews. Goldstein, Hannappel and Kleinman's account of the protein as an actin-sequestering molecule that 'moonlights' in tissue repair (PMID 16099219) is the standard orientation to the mechanism. Crockford and colleagues surveyed its structure, function and clinical development (PMID 20536467). Both are reviews: useful maps, not evidence.

All of this work used the parent protein.

How far thymosin beta-4 got in humans — and where TB-500 did not follow

This is the part usually left out, in both directions.

Thymosin beta-4 was taken into clinical development, including an injectable formulation with cardiac indications in view, and reached early-phase human testing. That is more than most compounds in this catalogue can claim, and it is a point in favour of the underlying biology being taken seriously by people who had to raise money against it.

It is also not an endpoint. The protein has not been approved for any indication by any regulator — not Health Canada, not the FDA, not the EMA. No completed trial has established a cardiac benefit in people. A development programme that reaches early-phase testing and stops is a programme that did not produce an approvable result, for reasons that may be scientific, commercial or both.

And the fragment did not go through any of it. There is no human trial of TB-500. The clinical history belongs to the parent protein, and citing it in support of the fragment is the substitution this article opened with.

What the fragment does and does not inherit

The pattern is that the fragment inherits the structural claim and nothing else automatically. 'Retains the actin-binding region' is a statement about sequence. Whether a seven-residue peptide reproduces the signalling behaviour of a 43-residue protein inside a cell is an empirical question, and for the cardiac endpoints above it has not been answered. Earlier versions of this article asserted that the ILK mechanism sits in a region the fragment contains; that is not established, so it is gone.

Where the evidence stops

The cardiac evidence is animal and cell-culture work on the parent protein. Mouse infarction models, followed over weeks. Mouse hearts beat several times faster than human hearts, scar differently and are injured on purpose in a laboratory rather than by decades of atherosclerosis.

'Reduced scarring' is a model endpoint, not a clinical one. Cardiac scar is mechanically load-bearing. Less of it is not automatically better — thin or badly remodelled scar can fail, and scar in the wrong place generates arrhythmias. The papers measure function and histology; the clinical meaning of those measures is exactly what human trials exist to settle, and here they do not exist.

Regeneration, in the strict sense, is not what was shown. Replacing lost cardiomyocytes with new ones remains an open problem in cardiac biology. The reported effects concern migration, survival and progenitor populations, which is a different and more modest claim.

TB-500 is not approved anywhere, for anything, and it is on the World Anti-Doping Agency's prohibited list, which matters to anyone who competes.

There is no published cardiac combination work with BPC-157. The mechanistic story often told — angiogenesis from one compound, cell migration from the other — is an argument, not a result. No study in this reference set examined the pair in a cardiac model. For the combination logic as it actually stands, see The Wolverine Stack Explained and The Wolverine Stack 1:1 Ratio.

For the compound and its actin biology, see What Is TB-500?; for the better-developed tissue thread, TB-500 for Tendon and Ligament Research; for the wider framing, Healing & Recovery Peptides Explained. Nothing here is medical, dosing, or therapeutic guidance.

TB-500 is supplied here as TB-500, and with BPC-157 in the Wolverine Stack; BPC-157 is also sold on its own for designs that are not 1:1. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.

Common questions

Does TB-500 repair heart damage? No published work supports saying so. The cardiac papers tested thymosin beta-4, the full protein, in mouse infarction models. No human trial of TB-500 exists for any indication, and no regulator has approved either molecule for cardiac use.

But thymosin beta-4 was in human trials — doesn't that count? It counts for thymosin beta-4, and only as far as early-phase testing with no approval at the end of it. It does not transfer to a seven-residue fragment that was never in those trials. The two are related molecules, not the same molecule.

What did the 2004 Nature paper actually report? Migration of cardiac cells and cardiac progenitors, improved cell survival, activation of integrin-linked kinase as the pathway, and better function with less scarring in a mouse infarction model. The 'survival' in that paper's findings is cell survival; it is often misreported as animal survival.

Why does the fragment-versus-protein distinction matter so much here? Because the cardiac findings are signalling findings, not just binding findings. ILK activation and progenitor mobilisation were demonstrated with the whole protein. A fragment chosen for an actin-binding motif may or may not do those things, and nobody has published the experiment.

Selected Research References

1. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin Beta-4 Activates Integrin-Linked Kinase and Promotes Cardiac Cell Migration, Survival and Cardiac Repair. Nature. 2004;432(7016):466-472. pubmed.ncbi.nlm.nih.gov/15565145
2. Goldstein AL, Hannappel E, Kleinman HK. Thymosin Beta-4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues. Trends in Molecular Medicine. 2005;11(9):421-429. pubmed.ncbi.nlm.nih.gov/16099219
3. Crockford D, Turjman N, Allan C, Angel J. Thymosin Beta-4: Structure, Function, and Biological Properties Supporting Current and Future Clinical Applications. Annals of the New York Academy of Sciences. 2010;1194:179-189. pubmed.ncbi.nlm.nih.gov/20536467
4. Smart N, Risebro CA, Melville AAD, et al. Thymosin Beta-4 Induces Adult Epicardial Progenitor Mobilization and Neovascularization. Nature. 2007;445(7124):177-182. (Reference on epicardial progenitor cell biology in cardiac repair.)

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.